Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Utah for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Utah only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Utah (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ron Lord (NPI 1790991107)

Field	Value
Entity Type	Individual
Organization	Ron Lord
Address	585 E Riverside Drive
City	St. George
State	UT
ZIP	84790
Taxonomy	Ophthalmology Physician
NPI Enumerated	May 15, 2007

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

RON LORD is an ophthalmology physician in ST. GEORGE, UT with lifetime Medicare revenue of $3.2M and no Medicaid billing on file, making the provider effectively single‑payer (Medicare) from a claims perspective; the NPI was enumerated 2007-05-15 (~19 years ago), indicating a long-tenured practice. This payer concentration has direct implications for contracting and access analyses because there is no Medicaid activity to evaluate against in‑state networks.

Revenue is heavily concentrated in a small set of intravitreal drug codes: J2777 ($859.6K, 27.0%), J0178 ($795.8K, 25.0%), and J2778 ($423.3K, 13.3%) together account for 65.2% of this provider’s Medicare revenue, per the precomputed top‑3 share. That concentration signals dependence on high-volume, high-cost retinal injection therapy as the core revenue driver.

The code mix points to a retina-focused, injection‑centric outpatient operation: the top revenue generators (J2777, J0178, J2778) are anti‑VEGF or related intravitreal therapeutics administered in-office, and 67028 (2.8K claims, $265.9K, 8.3%) further reflects high throughput for isolated intravitreal injections. Operational implications include sizeable drug acquisition/administration logistics and steady clinic throughput needs (chair time, injection suites, sterile prep).

Diagnostic and clinic volume are unusually high relative to peers: 92134 (4.7K claims, $132.7K, 4.2%) ranks #61 of 26868 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), and 92014 (1.5K claims, $122.3K, 3.8%) ranks #649 of 35415 providers nationally (98th percentile; extreme outlier). Together these indicate heavy use of retinal imaging and high established‑patient exam volumes consistent with a high‑throughput retinal practice model rather than a primarily surgical ambulatory practice.

Competitive standing across injection agents is mixed: J2778 ranks #173 of 1208 providers nationally (86th percentile; typical, unremarkable volume) and J2777 ranks #304 of 2039 (85th percentile; typical), indicating above‑average national participation in ranibizumab and faricimab, while J0178 ranks #1133 of 3204 (65th percentile; typical) showing more modest aflibercept volume versus peers. In contrast, billing for bevacizumab (J9035, $117.1K, 3.7%) is an extreme outlier — ranks #14 of 1852 providers nationally (99th percentile; extreme outlier, far above typical national volume) — suggesting atypically high use of this agent relative to national peers.

While injections and imaging dominate, the provider does maintain procedural/surgical capacity at lower volumes: cataract extraction 66984 (117 claims, $36.6K, 1.1%) sits near the median (54th percentile) and posterior-segment procedures such as 67042 (38 claims, $31.5K, 1.0%) rank #176 of 1087 providers nationally (83rd percentile; typical). These data indicate the practice performs some surgical retina and cataract procedures but that these are not the primary revenue engine compared with anti‑VEGF and imaging services.

The absence of any Medicaid billing on file is a salient payer‑mix signal: with Medicare $3.2M in lifetime revenue and no Medicaid claims, the practice will appear as essentially Medicare‑only in payer network analyses and may be underrepresented in Medicaid access studies. For payers, this gap suggests limited value in using this provider to expand Medicaid network capacity without new contracting or credentialing activity.

Tenure and the combination of extreme imaging/exam volumes with very high injection counts imply an established, high-throughput retinal clinic model: long NPI tenure (2007-05-15 (~19 years ago)) plus extreme outlier volumes on 92134 and several injection codes support an operational profile of frequent follow-up visits, routine retinal imaging workflows, and large in‑office drug administration throughput. That profile should be prioritized when modeling appointment capacity, drug purchasing, and negotiated injection reimbursement terms.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

24 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2777	Injection, faricimab‑svoa, 0.1 mg	29,640	$30	$859.6K
J0178	Injection, aflibercept, 1 mg	1,150	$690	$795.8K
J2778	Injection, ranibizumab, 0.1 mg	2,370	$180	$423.3K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,800	$100	$265.9K
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	1,520	$120	$181.8K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	4,740	$30	$132.7K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	1,470	$80	$122.3K
J9035	Injection, bevacizumab, 10 mg	2,130	$60	$117.1K
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	510	$160	$80.2K
66984	The provider inserts an artificial lens after removing an extracapsular cataract by aspiration or use of ultrasonic waves. This procedure is done without the use of an endoscopic laser probe to…	120	$310	$36.6K

Showing 1–10 of 24

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 24 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Utah Distribution

Ron Lord — 5 of 24 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Utah

Full comparison — all codes billed, vs. state median

24 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	8	40	620	$690	$683.2K
J2777	7	20	13,140	$30	$523.9K
J2778	2	10	870	$180	$224.3K
J2781	2	20	960	$120	$126.6K
66984	59	150	90	$520	$80.3K
67028	2	60	440	$90	$61.7K
J7312	2	10	340	$160	$52.7K
67042	3	20	20	$1,100	$26.3K
67036	9	20	20	$1,010	$24.2K
67108	3	10	20	$1,090	$18.6K

Showing 1–10 of 24

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ron Lord, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ihc Health Services, Inc.	UT	Children's Hospital	$0	$129.5M
Ihc Health Services, Inc.	UT	General Acute Care Hospital	$0	$68.7M
Ihc Health Services, Inc.	UT	General Acute Care Hospital	$0	$65.8M
Ihc Health Services Inc	UT	General Acute Care Hospital	$0	$54.1M
Ihc Health Services, Inc.	UT	General Acute Care Hospital	$0	$44.3M
Ihc Health Services Inc	UT	Home Infusion Therapy Pharmacy	$0	$38.1M
Ihc Health Services Inc	UT	Durable Medical Equipment & Medical Supplies	$0	$26.9M
Ihc Health Services Inc	UT	General Acute Care Hospital	$0	$25.3M
Ihc Health Services, Inc.	UT	Clinical Medical Laboratory	$2.7M	$17.9M
Ihc Health Services, Inc.	UT	General Acute Care Hospital	$0	$20.4M

Nearby Providers

Other providers in the same ZIP code as Ron Lord, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Southwest Utah Community Health Center	UT	Federally Qualified Health Center (FQHC)	$0	$7.3M
Zion Eye Institute, Inc	UT	Ambulatory Surgical Clinic/Center	$6.1M	$19.7K
Summit Behavior Services	UT	Counselor	$0	$5.4M
Ihc Health Services Inc	UT	Multi-Specialty Clinic/Center	$0	$4.4M
Joshua Carlson	UT	Retina Specialist (Ophthalmology) Physician	$2.6M	$0
St George Surgical Center LP	UT	Ambulatory Surgical Clinic/Center	$2.5M	$0
Coral Desert Surgery Center LLC	UT	Ambulatory Surgical Clinic/Center	$2.5M	$17.8K
Ihc Health Services Inc	UT	Clinical Medical Laboratory	$2.4M	$42.7K
Jerry D Twiggs Md PC	UT	Pediatric Adolescent Medicine Physician	$0	$2.2M
Ihc Health Services Inc	UT	Pediatrics Physician	$0	$2.1M

Ron Lord — Billing Profile & Reimbursement Data

Sign up for Ron Lord — Billing Profile & Reimbursement Data policy alerts

Ron Lord — Billing Profile & Reimbursement Data

Sign up for Ron Lord — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References